Santen Pharmaceutical Co. Ltd
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertensio… Read more
Santen Pharmaceutical Co. Ltd (SNPHF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: 0.066x
Based on the latest financial reports, Santen Pharmaceutical Co. Ltd (SNPHF) has a cash flow conversion efficiency ratio of 0.066x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($18.89 Billion) by net assets ($285.18 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Santen Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Santen Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Santen Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Santen Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Allreal Holding
SW:ALLN
|
0.034x |
|
Quálitas Controladora S.A.B. de C.V
OTCGREY:QUCOF
|
0.103x |
|
Celcuity LLC
NASDAQ:CELC
|
-0.383x |
|
PrairieSky Royalty Ltd
PINK:PREKF
|
0.033x |
|
CALIFORNA RESOURC. DL-01
F:1CLD
|
N/A |
|
Shenzhen Sunlord Electronics Co Ltd
SHE:002138
|
0.078x |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
-0.019x |
|
Voestalpine AG
PINK:VLPNF
|
0.042x |
Annual Cash Flow Conversion Efficiency for Santen Pharmaceutical Co. Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of Santen Pharmaceutical Co. Ltd from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $285.18 Billion | $60.93 Billion | 0.214x | -10.20% |
| 2024-03-31 | $305.37 Billion | $72.65 Billion | 0.238x | +87.84% |
| 2023-03-31 | $293.30 Billion | $37.15 Billion | 0.127x | -7.34% |
| 2022-03-31 | $336.84 Billion | $46.04 Billion | 0.137x | +8.15% |
| 2021-03-31 | $307.05 Billion | $38.81 Billion | 0.126x | -4.27% |
| 2020-03-31 | $302.56 Billion | $39.95 Billion | 0.132x | +17.43% |
| 2019-03-31 | $292.57 Billion | $32.89 Billion | 0.112x | -24.54% |
| 2018-03-31 | $287.56 Billion | $42.84 Billion | 0.149x | +248.85% |
| 2017-03-31 | $253.88 Billion | $10.84 Billion | 0.043x | -50.70% |
| 2016-03-31 | $260.01 Billion | $22.52 Billion | 0.087x | -27.73% |
| 2015-03-31 | $211.78 Billion | $25.39 Billion | 0.120x | -16.32% |
| 2014-03-31 | $181.21 Billion | $25.96 Billion | 0.143x | +137.93% |
| 2013-03-31 | $165.13 Billion | $9.94 Billion | 0.060x | -53.80% |
| 2012-03-31 | $164.86 Billion | $21.48 Billion | 0.130x | +14.70% |
| 2011-03-31 | $156.40 Billion | $17.77 Billion | 0.114x | -40.13% |
| 2010-03-31 | $137.60 Billion | $26.11 Billion | 0.190x | +100.76% |
| 2009-03-31 | $125.37 Billion | $11.85 Billion | 0.095x | -22.33% |
| 2008-03-31 | $127.12 Billion | $15.47 Billion | 0.122x | +4.64% |
| 2007-03-31 | $128.65 Billion | $14.96 Billion | 0.116x | -33.92% |
| 2006-03-31 | $118.64 Billion | $20.88 Billion | 0.176x | +187.78% |
| 2005-03-31 | $108.24 Billion | $6.62 Billion | 0.061x | -- |